• Biomimetic Nanotherapy for Metastatic TNBC

  2026-08-24

  The ACS Nano study developed a biomimetic mesoporous silica nanoplatform that combines photothermal tumor ablation with tumor vaccination and immune checkpoint modulation. Its significance lies in coordinating tumor targeting, stimulus-responsive cargo release, and immune remodeling to address recurrence and metastasis rather than treating the primary tumor alone.

• Losmapimod: Rethinking p38 MAPK Translation

  2026-08-24

  Losmapimod and its synonym GW856553X offer translational researchers a defined way to interrogate p38α/β signaling across inflammation, vascular biology, hypertension, and COPD research. This article connects established pharmacology with emerging evidence that inhibitor-driven kinase conformation can influence dephosphorylation dynamics, while separating demonstrated findings from testable hypotheses.

• KNUCKLES Controls Floral Meristem Termination

  2026-08-23

  This Arabidopsis study identifies KNUCKLES as an epigenetic coordinator that terminates floral meristem activity by repressing WUS, CLV3, PIN1, and IPT7. Its central contribution is to connect stem-cell circuitry with spatial auxin distribution and cytokinin activity, providing a mechanistic explanation for how floral determinacy is timed.

• BIRB 796: Practical p38α MAPK Research Workflows

  2026-08-22

  BIRB 796 (Doramapimod) combines potent allosteric p38α MAPK inhibition with a useful experimental profile for inflammation research, cytokine production inhibition, and apoptosis assays. This guide converts its biochemical selectivity and emerging dephosphorylation insights into practical cell-based workflows, controls, and troubleshooting decisions.

• AZD0156: ATM Kinase Inhibitor Workflows

  2026-08-21

  Build reproducible DNA damage response and metabolic-adaptation assays with AZD0156, a highly selective ATM kinase inhibitor. This workflow connects checkpoint control, DNA double-strand break repair, macropinocytosis, and nutrient rescue experiments for cancer therapy research.

• SP600125 JNK Inhibitor Workflows for Redox Research

  2026-08-20

  SP600125 enables controlled interrogation of JNK-regulated c-Jun phosphorylation, cytokine signaling, apoptosis, and inflammation alongside redox stress measurements. This practical guide connects the compound’s established kinase profile with the progressive Nrf2 loss reported during rotavirus infection, while emphasizing assay controls, timing, and solubility management.

• Oltipraz and Nrf2: A MASLD Assay Framework

  2026-08-20

  Oltipraz is a phase II enzyme inducer that provides a useful mechanistic probe for Nrf2-centered liver research. This article translates findings from a recent MASLD mouse study into a practical, evidence-aware framework for separating redox signaling, autophagy, and ferroptosis assays.

• EZ Cap™ Firefly Luciferase mRNA Workflow

  2026-08-19

  Use a Cap1- and poly(A)-optimized reporter to separate mRNA delivery, translation, viability, and assay timing in cell and animal studies. This workflow shows how to benchmark LNP performance, build gene regulation reporter assays, and troubleshoot weak or variable bioluminescence without confusing reporter output with therapeutic efficacy.

• SP600125: A Practical JNK Inhibitor Workflow

  2026-08-19

  SP600125 helps dissect how TLR2/TLR4 signals connect to JNK-driven cytokine production in monocyte inflammation models. This guide translates its biochemical selectivity into a practical workflow for pathway timing, cytokine expression modulation, apoptosis assay controls, and troubleshooting.

• Self-Amplifying RNA Vaccines for Influenza: Study Insights

  2026-08-18

  A 2026 study found that self-amplifying RNA produced strong, durable, and dose-sparing protection against influenza B in mice, where conventional mRNA performed poorly. Its central contribution is a direct comparison of nucleoside-modified mRNA, self-amplifying RNA, and circular RNA platforms across influenza subtypes.

• Fluorouracil: From DNA Stress to Immune Strategy

  2026-08-18

  A translational perspective on Fluorouracil (5-Fluorouracil, Adrucil), connecting thymidylate synthase inhibition and DNA replication stress with Wnt/β-catenin biology, immune context, and practical oncology research workflows.

• Kir4.1–Panx3 Signaling in Orofacial Neuropathic Pain

  2026-08-17

  This study identifies a mechanistic link between reduced Kir4.1 activity in trigeminal satellite glial cells and Panx3-dependent orofacial neuropathic pain. Using chronic constriction injury of the infraorbital nerve, genetic manipulation, and ROS–p38 MAPK analyses, the authors position Panx3 downstream of a redox-sensitive glial signaling pathway.

• XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum

  2026-08-17

  A 2026 Hematology study shows that inhibiting XPO1 with selinexor increases the response of diffuse large B-cell lymphoma models to cisplatin and oxaliplatin. The strongest combination effects occurred in germinal-center B-cell-like DLBCL, where platinum-associated apoptosis, reactive oxygen species accumulation, DNA-damage signaling, and stress-response pathways were amplified.

• Dinaciclib: From CDK Inhibition to Tissue Mechanics

  2026-08-16

  Explore how Dinaciclib and SCH727965 can support mechanistic cancer research beyond conventional cell-cycle assays. This article connects multi-CDK inhibition with apoptosis, Rb signaling, and the interpretation of tissue-boundary phenotypes revealed by quantitative developmental biology.

• Dual-Action p38α Inhibitors and Dephosphorylation

  2026-08-15

  The reference study shows that selected kinase inhibitors can both suppress p38α catalytic activity and accelerate WIP1-mediated removal of the activation-loop phosphate. Biochemical measurements and X-ray structures connect this effect to stabilization of a phosphatase-accessible activation-loop conformation, suggesting a framework for designing more durable and selective kinase inhibitors.

8558 records 1/571 page Next 12345 下5页 Last page